Skip to content

Study · In vitro (cells) · 2005

4 results

Immunomodulatory activities of small host defense peptides.

Bowdish DM, Davidson DJ, Scott MG, Hancock RE

Antimicrobial agents and chemotherapy1 May 2005Cited by 240 (Europe PMC)

PMID15855488 (opens in a new tab)PMCIDPMC1087655 (opens in a new tab)DOI10.1128/aac.49.5.1727-1732.2005 (opens in a new tab)PepBankPUB-15855488
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In human THP-1 cells, LL‑37 inhibited LPS-induced TNF-alpha secretion.

    In plain wordsIn lab-grown human immune cells, LL‑37 reduced TNF-alpha release triggered by bacterial LPS.

    Peptide
    LL-37
    Outcome
    DecreaseLPS-induced TNF-alpha secretion
    Study

    humann: not reported in source

    THP-1 human macrophage/monocyte-like cells
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Indolicidin, like LL-37, inhibited LPS-induced tumor necrosis factor alpha (TNF-alpha) secretion, even when added up to an hour after the addition of Escherichia coli O111:B4 LPS to the human macrophage/monocyte-like THP-1 cell line.
    1 context sentence
    Summary · context
    To investigate if these properties are shared by smaller peptides, two cathelicidin peptides derived from bovine neutrophils, the 13-mer indolicidin and Bac2A, a linear 12-amino-acid derivative of bactenecin, were compared to the 37-amino-acid peptide LL-37.
  2. 02LabIn vitro (cells)Activity measurement

    In a human bronchial cell line, LL‑37 induced production of the chemokine interleukin-8.

    In plain wordsIn a lab-grown human airway cell line, LL‑37 triggered production of the signal protein IL-8.

    Peptide
    LL-37
    Outcome
    IncreaseIL-8 production in bronchial cells
    Study

    humann: not reported in source

    16HBE14o(-) human bronchial cell line
    Outcome group
    Immune response · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Indolicidin was analogous to LL-37 in its ability to induce the production of the chemokine interleukin-8 (IL-8) in a human bronchial cell line, 16HBE14o(-)
    1 context sentence
    Summary · context
    To investigate if these properties are shared by smaller peptides, two cathelicidin peptides derived from bovine neutrophils, the 13-mer indolicidin and Bac2A, a linear 12-amino-acid derivative of bactenecin, were compared to the 37-amino-acid peptide LL-37.
  3. 03LabIn vitro (cells)Activity measurement

    In human THP-1 cells, LL‑37 was not chemotactic at concentrations between 10 and 100 µg/ml.

    In plain wordsIn lab-grown human immune cells, LL‑37 did not attract the cells at 10 to 100 µg/ml.

    Peptide
    LL-37
    Outcome
    No significant changeChemotaxis of THP-1 cells
    Study

    humann: not reported in source

    THP-1 human macrophage/monocyte-like cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    10-100 µg/mlAs given in this study (human).

    Measurements

    Concentration range tested
    10 to 100 µg/ml
    THP-1 cells

    Source sentences

    Summary
    Conversely, Bac2A was chemotactic for THP-1 cells at concentrations between 10 and 100 mug/ml, while indolicidin and LL-37 were not chemotactic at these concentrations for THP-1 cells.
    1 context sentence
    Summary · context
    To investigate if these properties are shared by smaller peptides, two cathelicidin peptides derived from bovine neutrophils, the 13-mer indolicidin and Bac2A, a linear 12-amino-acid derivative of bactenecin, were compared to the 37-amino-acid peptide LL-37.

Studies that did not test the peptide alone1

In this study, LL-37 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking LL-37.

  1. 04LabNot a test of LL-37 aloneIn vitro (cells)Activity measurement

    In human THP-1 cells, indolicidin and LL‑37 together acted synergistically at low concentrations to suppress LPS-induced TNF-alpha production.

    In plain wordsIn lab-grown human immune cells, indolicidin and LL‑37 together, at low concentrations, reduced LPS-triggered TNF-alpha more than expected.

    Peptide
    LL-37
    Outcome
    DecreaseLPS-induced TNF-alpha production, indolicidin plus LL-37
    Study

    humann: not reported in source

    THP-1 human macrophage/monocyte-like cells
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    At low concentrations, indolicidin and LL-37 acted synergistically to suppress LPS-induced production of TNF-alpha.
    1 context sentence
    Summary · context
    To investigate if these properties are shared by smaller peptides, two cathelicidin peptides derived from bovine neutrophils, the 13-mer indolicidin and Bac2A, a linear 12-amino-acid derivative of bactenecin, were compared to the 37-amino-acid peptide LL-37.

    In this study, LL-37 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LL-37.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.